MSL
VRTX icon

Mackay Shields LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Mackay Shields LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-36,585
Closed -$9.55M – 688
2022
Q1 		$9.55M Sell
36,585
-1,398
-4% -$332K 0.08% 228
2021
Q4 		$8.34M Sell
37,983
-1,594
-4% -$310K 0.07% 260
2021
Q3 		$7.18M Sell
39,577
-1,146
-3% -$224K 0.07% 260
2021
Q2 		$8.21M Sell
40,723
-9,706
-19% -$2.03M 0.08% 242
2021
Q1 		$10.8M Sell
50,429
-8,195
-14% -$1.8M 0.08% 265
2020
Q4 		$13.9M Sell
58,624
-34,235
-37% -$7.85M 0.1% 239
2020
Q3 		$25.3M Buy
92,859
+47,931
+107% +$13.2M 0.17% 124
2020
Q2 		$13M Sell
44,928
-33,669
-43% -$9.13M 0.1% 228
2020
Q1 		$18.7M Buy
78,597
+34,837
+80% +$7.99M 0.17% 146
2019
Q4 		$9.58M Sell
43,760
-3,785
-8% -$766K 0.07% 337
2019
Q3 		$8.05M Buy
47,545
+2,944
+7% +$521K 0.05% 389
2019
Q2 		$8.18M Buy
44,601
+338
+0.8% +$59.1K 0.06% 391
2019
Q1 		$8.14M Buy
44,263
+5,568
+14% +$1.03M 0.06% 379
2018
Q4 		$6.41M Sell
38,695
-2,067
-5% -$358K 0.05% 418
2018
Q3 		$7.86M Sell
40,762
-480
-1% -$85.5K 0.06% 358
2018
Q2 		$7.01M Sell
41,242
-1,326
-3% -$206K 0.05% 413
2018
Q1 		$6.94M Buy
+42,568
New +$6.95M 0.04% 438

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Mackay Shields LLC's VRTX Position: Q2 2022 in Review

Mackay Shields LLC sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 36,585 shares — an estimated $9.55M sold.

Mackay Shields LLC first reported a position in VRTX in Q1 2018 and held it in 17 quarters. The position peaked at $25.3M in Q3 2020. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Mackay Shields LLC reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Mackay Shields LLC sold 36,585 Vertex Pharmaceuticals shares in Q2 2022, an estimated $9.55M.
  • Mackay Shields LLC first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 17 quarters.
  • Mackay Shields LLC's Vertex Pharmaceuticals position peaked at $25.3M in Q3 2020.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Mackay Shields LLC's 13F filing for Q2 2022, filed 3 Aug 2022.